These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11065146)

  • 1. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas).
    Pfaller MA; Jones RN
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():25-37. PubMed ID: 11065146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections.
    Pfaller MA; Jones RN
    J Antimicrob Chemother; 2000 Aug; 46 Suppl B():25-37. PubMed ID: 10969060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview.
    Turner PJ
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():9-23. PubMed ID: 11065145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. MYSTIC Study Group (European centres only).
    Goossens H
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():39-52. PubMed ID: 11065147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
    Rhomberg PR; Jones RN; Sader HS; Fritsche TR;
    Diagn Microbiol Infect Dis; 2004 Aug; 49(4):273-81. PubMed ID: 15313533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
    Turner PJ
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
    Jones RN; Mendes C; Turner PJ; Masterton R
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):247-56. PubMed ID: 16360548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
    Korten V; Ulusoy S; Zarakolu P; Mete B;
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
    Rhomberg PR; Deshpande LM; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):425-32. PubMed ID: 17662557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002).
    Turner PJ
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):281-9. PubMed ID: 15808320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):414-26. PubMed ID: 19833471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteraemia in Europe--antimicrobial susceptibility data from the MYSTIC surveillance programme.
    Unal S; Masterton R; Goossens H
    Int J Antimicrob Agents; 2004 Feb; 23(2):155-63. PubMed ID: 15013041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program.
    Mendes C; Hsiung A; Kiffer C; Oplustil C; Sinto S; Mimica I; Zoccoli C;
    Braz J Infect Dis; 2000 Oct; 4(5):236-44. PubMed ID: 11063555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
    Jones RN; Kirby JT; Rhomberg PR
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007).
    Patzer JA; Dzierzanowska D; Turner PJ
    J Antimicrob Chemother; 2008 Aug; 62(2):369-75. PubMed ID: 18445575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.
    Unal S; Garcia-Rodriguez JA
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):265-71. PubMed ID: 16360550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types.
    Goossens H
    J Antimicrob Chemother; 2000 Aug; 46 Suppl B():39-52. PubMed ID: 10969061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.